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NeutrophilThe ability of IL-6 to signal via both membrane bound and soluble receptors is thought to explain the
capacity of this cytokine to act in both the initiation and resolution of acute inﬂammatory responses. In cystic
ﬁbrosis (CF), poorly resolved neutrophillic inﬂammation of the lungs is a primary cause of morbidity and
mortality. Expression of IL-6 has been reported to be low in CF lung secretions, despite ongoing
inﬂammation, but the status of soluble IL-6 receptor (sIL-6R) in these patients is unknown. We hypothesised
that sIL-6R may be an important potentiator of IL-6 activity in CF associated lung disease. IL-6, sIL-6R and
sgp130 (a natural antagonist of responses mediated by the sIL-6R) were analysed by ELISA and Western blot
in bronchoalveolar lavage ﬂuid (BALF) from 28 paediatric CF patients and nine non-CF controls. Total cell
counts in CF were four fold higher compared to controls (median: 1.4×106 cells/ml v. 0.35×106 cells/ml in
controls) (pb0.001) and the inﬁltrate was dominated by neutrophils which were elevated by 89 fold
(0.62×106 cells/ml v. 0.007×106 cells/ml in controls) (pb0.001). Other markers of inﬂammation such as IL-
8 and MCP-1 were elevated 17.5 and 3.8 fold respectively (IL-8; median: 1122 pg/ml v. 64 pg/ml in controls,
pb0.01 and MCP-1; median: 692 pg/ml v. 182 pg/ml in controls, pb0.05). IL-6, although present in 23/32 CF
BALF specimens compared to 1/9 controls (pb0.01), was weakly expressed (median: 50 pg/ml). Expression
of sIL-6R and sgp130 in CF was no different to control patients. We tested whether weak expression of all
three molecules was due to degradation by CF BALF. Degradative activity was observed in association with
BALF elastase activity and could be speciﬁcally blocked by serine protease inhibitors. Degradation of sIL-6R
by puriﬁed serine proteases (elastase, cathepsin G and proteinase 3) was also observed leading to a loss of
trans-signalling activity. Interestingly, sIL-6R was protected from proteolysis by interaction with IL-6. Our
data identify and deﬁne a novel protease mediated deﬁciency of IL-6 signalling in the CF lung.receptor; IL-6R, IL-6 receptor;
id; NE, neutrophil elastase; CG,
T, alpha-1 anti-trypsin; MMP,
e protease
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The importance of IL-6 as a central orchestrator of inﬂammatory
responses is highlighted by its ability to inﬂuence both the initiation
and resolution of inﬂammation at a number of sites, including the
lung [1,2]. This functional pleiotropy is thought to be due to the
inducible expression of a soluble IL-6 receptor (sIL-6R) which acts as
an agonist for IL-6 activity [3,4]. IL-6 responsiveness normally requires
a membrane bound receptor complex, composed of a ligand binding
α-chain IL-6 receptor (IL-6R) and a β-chain gp130 signalling receptor[4]. However, sIL-6R arising either through regulated cleavage of
membrane bound receptor [5], or through de novo synthesis of a
differentially spliced isoform (DSsIL-6R) [6,7], interacts with IL-6 to
form a highly active agonistic complex which can signal via gp130,
independently of membrane anchored IL-6R. This process has been
named trans-signalling [8].
In contrast to gp130, which is found on all cell types, membrane
bound IL-6R is expressed by a limited spectrum of cells, primarily
restricted to leukocytes and hepatocytes [9]. Induced sIL-6R expres-
sion therefore confers IL-6 responsiveness on the great majority of cell
types in the body which lack a cognate membrane bound receptor [4].
Furthermore, sIL-6R enhances IL-6 activity in vivo by 10–100 fold [10],
permitting potent responses to even very low doses of IL-6, such as
those found in the CF lung. This quantitative and qualitative
modulation of IL-6 activity enables sIL-6R to extensively shape
inﬂammatory events. Speciﬁc blockade of IL-6 trans-signalling in
vivo with a naturally occurring antagonist, soluble gp130 (sgp130),
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acute inﬂammatory responses. In models of peritoneal inﬂammation,
IL-6 trans-signalling shifts the balance of leukocyte recruitment away
from neutrophil dominated recruitment in favour of mononuclear
cells [1,11] by modifying chemokine expression [12] and neutrophil
apoptosis [13], a pivotal step in the resolution of acute innate
inﬂammatory responses. Furthermore, intra-tracheal administration
of IL-6 attenuates LPS induced pulmonary neutrophil inﬁltration [2].
This is particularly relevant to CF as chronic neutrophil dominated
inﬂammation of the lungs due to recurrent and poorly resolved
infectious episodes [14,15], an apparent propensity for excessive
neutrophil recruitment by the CF lung [16] and dysregulated
neutrophil apoptosis, leads to progressive lung disease and is the
primary cause of morbidity and mortality in these patients [17].
Furthermore, although IL-6 is found at high concentrations in a range
of inﬂammatory diseases [18–20] expression in lung secretions from
CF patients is notably low despite evidence of signiﬁcant inﬂamma-
tory activity [21–23].
In this study we examine the expression of IL-6 trans-signalling
molecules in bronchoalveolar lavage ﬂuid (BALF) from CF and control
patients. We describe the relationship between expression of these
molecules and other inﬂammatory markers in these patient groups
and deﬁne a novel deﬁciency of the IL-6 trans-signalling pathway in
CF patients.
2. Materials and methods
2.1. Reagents
All reagents were from Fisher Scientiﬁc, UK unless otherwise
indicated. Plasma derived AAT (Prolastin) was from Talecris Biother-
apeutics, NC. GM6001 (Galardin) was from Calbiochem, UK. PMSF and
1,10-phenanthroline were from Sigma, UK. Puriﬁed neutrophil
elastase (NE), cathepsin G (CG) and proteinase 3 (PR3) were from
Athens Research and Technology, GA. Recombinant human IL-6, sIL-
6R and sgp130 were from R&D Systems, UK.
2.2. Patients and clinical samples
Patient material was obtained following approval from the South
East Wales Research Ethics Committee. 32 samples were obtained
from 28 children with CF (median age 6.2 years, IQR: 1.8–10.4). For
13/32 samples from CF patients, bronchoalveolar lavage (BAL) was
performed by ﬂexible bronchoscopy for clinical investigation of new
respiratory symptoms or persistent respiratory symptoms which
were refractory to current treatment. For 18/32 samples, non-
bronchoscopic lavage was performed while the patient was under
general anaesthesia for a surgical procedure not related to respiratory
symptoms, most commonly insertion or removal of a portacath but
also for gastrostomy insertion, bowel re-anastamosis and meconium
ileus surgery. BAL methodology information was unavailable for 1 CF
patient in the study. BAL was performed by non-bronchoscopic lavage
on nine control patients (median age 8.3 years, IQR 4.2–9.1)whowere
recruited from children under general anaesthetic for the surgical
removal of tonsils or adenoids. Although upper airway symptoms had
been present leading up to the surgery, all control children were
reported to be well at the time of surgery, had no underlying chest
problems and were not on medication. Lavage was performed using
1 ml normal saline/kg body weight (up to a maximum of 20 ml).
Following collection all BALF samples were kept on ice. Cellular
material and BAL supernatants were separated by centrifugation at
500 g for 5 min. Supernatants were stored at−70 °C in 25 μl aliquots
to avoid multiple freeze thaw cycles during subsequent analyses;
storage occurred within 45 min of collection. Cellular material was
resuspended in PBS and treatedwith 50 μg/ml dithiothreitol (DTT) for
15 min at room temperature to dissociate any excess mucous prior totaking a total cell count by haemocytometer. Differential cell counts
were performed by light microscopy on Wright–Giemsa stained
cytospins by counting a minimum of 300 total events in four separate
ﬁelds. Total cell counts were available for 26 samples and reliable
differential cell counts could be enumerated for 21 CF samples and 7
controls. Where differential counts could not be obtained, this was
due to the absence of a total cell count, lack of sufﬁcient specimen for
cytospins or the presence of excessive mucus and cell clumping in the
sample (despite DTT treatment).
2.3. Cell isolation, culture and stimulation
A549 alveolar epithelial cells from the European Collection of Cell
Cultures (ECACC, UK) were cultured in Kaighns-F12 medium
(Hyclone, UK) supplemented with 5% heat inactivated foetal calf
serum (Invitrogen-Gibco, UK), 100 U/ml Penicillin/Streptomycin,
1 mM Sodium Pyruvate (Hyclone, UK). Cells at 70% conﬂuency were
cultured in DMEM without serum for 18 h prior to the addition of
stimulants. Cells were then cultured in serum free DMEMwith 30 ng/
ml each of native recombinant IL-6, sIL-6R or IL-6 in combination with
sIL-6R. IL-6 in combination with sIL-6R which had been treated with
500 mM CG for 2 h at 37 °C was also used as a stimulus. CG activity
was neutralised with 50 μg/ml AAT prior to adding IL-6. Supernatants
were collected at 18 h, cleared by centrifugation and cell free aliquots
were prepared for analysis.
Neutrophils were isolated from citrated human blood obtained from
healthy adult donors. Red blood cellswere sedimentedusing6%Dextran
BSS (Baxter Healthcare, IL). The leukocyte fraction was layered onto
Histopaque-1077(Sigma,UK) and centrifuged at1000 rpm/20min. The
neutrophil pellet was isolated and washed with serum free RPMI 1640.
Cells were cultured at a density of 2×106 cells/ml in serum free RPMI.
2.4. ELISA
IL-6, sIL-6R and sgp130 were measured using DuoSet ELISA kits
(R&D Systems, UK) according to the manufacturer's instructions. IL-
8wasmeasuredusingBDOptiEIA IL-8 ELISAkit (BD,UK)andMCP-1was
measured using the CCL2 ELISA kit (eBioscience, San Diego, CA). BALF
was diluted in the range 1:3–1:12.5 v/v for CF and control samples. Post
development absorbance was read at 450 nm on a Dynex Revelation
MRX TC spectrophotometer (Dynex Technologies Ltd., UK).
2.5. Elastase activity assay
Elastase activity was determined as previously described [24].
Brieﬂy, BALF samples were diluted 1:10 or 1:100 in assay activity
buffer (0.5 M NaCl, 0.1 M Tris pH 7.5 with 0.05% Triton X100). A seven
point standard curve was created by two fold dilution of NE stock
solution from 40 nM to 0.625 nM. Chromogenic substrate Suc-Ala-
Ala-Pro-Val-pNA (Bachem, UK) in DMSO was diluted to 2 mM in
activity buffer. 100 μl of substrate was added to 100 μl of standards or
samples in a ﬂat bottomed 96-well plate (Elkay, UK). 100 μl of activity
buffer alone was included as a negative control.
Elastase mediated conversion of the chromogenic substrate was
measured using a Dynex Revelation MRX TC spectrophotometer
warmed to 30 °C and reading every minute at 405 nm. The change in
optical density/min in BALF samples were converted to nM Elastase
using the standard curve.
2.6. Cleavage assays
Tomeasure the ability of CF BALF to cleave IL-6, sIL-6R and sgp130,
300 ng/ml of recombinant IL-6, sIL-6R or sgp130 was incubated with
20% CF BALF (which had been cleared by centrifugation at
13,000 rpm/1 min) in Tris buffered saline (TBS; 154 mM NaCl,
50 mM Tris) for the indicated times at 37 °C. For analysis of the
Fig. 1. Total and differential cell counts in BALF from CF and control patients. A) Total cell counts were available in BALF from 26 CF and 9 control patients. B) and C) Cytospins
prepared from BALF from CF and control patients were stained withWright–Giemsa and used to enumerate PMN andMNC numbers in each BALF sample following light microscopy.
Relative numbers of PMNs, MNCs and other cell types were counted in all available samples. Cell counts were used to calculate total PMN and MNC numbers in the original BALF
sample. Differential cell counts were available in 21 CF patients and 7 controls. D) IL-8 and E) MCP-1 concentrations were measured in 32 BALF samples from CF patients and 9 BALF
samples from control patients using ELISA. Horizontal lines indicate medians. Horizontal lines indicate medians. *=pb0.05; **=pb0.01; ***=pb0.001.
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recombinant sIL-6R was incubated with the indicated concentrations
each of puriﬁed NE, CG or PR3 in TBS for the indicated times at 37 °C.
Where speciﬁc protease inhibitors were used, CF BALF was pre-
treated with the indicated concentrations of 1, 10-phenanthroline,
GM6001, PMSF or AAT for 30 min on ice prior to the addition of
recombinant proteins. All samples were diluted with non-reducing
Laemmli buffer and boiled for 3 min. Antigens were detected by SDS-
PAGE followed by Western blotting.
2.7. SDS-PAGE and Western blotting
Samples containing IL-6, sIL-6R and sgp130 were resolved on 20%
and 15% and 10% polyacrylamide gels respectively. Proteins were
transferred to nitrocellulose membranes by electroblotting, blocked in
PBS/5% milk for 30 min and incubated with goat anti-IL-6 (Peprotech),goat anti-IL-6R (R&D Systems) or rabbit anti-gp130 (Santa Cruz
Biotechnology Inc., CA) for 1 h at room temperature or overnight at
4 °C. Blots were washed sequentially with PBS/0.05% Tween and PBS
followed by incubation with HRPO-conjugated secondary antibodies
against goat or rabbit IgG (Jackson ImmunoResearch,UK) for 1 h at room
temperature. Blotswere againwashedandantigensweredetectedusing
Kodak X-OMAT ﬁlmwith ECL substrate (Pierce Biotechnology, IL). Blots
were scanned and brightness and contrast were adjusted using Adobe
Photoshop. For clarity of presentation the order of individual lanes in
Figs. 3C and 4B has been rearranged. Densitometry was performed on
scanned blots using Image J (v1.37) software.
2.8. Measurement of apoptosis
Neutrophil apoptosis was assessed by ﬂow cytometry on a BD
FACSCalibur (Becton Dickinoson, MA, USA) using Annexin V-PE (MBL,
Fig. 2. IL-6, sIL-6R and sgp130 expression in BALF from CF and control patients. A) IL-6, B) sIL-6R and C) sgp130 concentrations were measured in 32 BALF samples from CF patients
and 9 BALF samples from control patients using ELISA. Horizontal lines indicate medians. **=pb0.01.
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Supernatants were harvested at the indicated time points, centrifuged
and cell free aliquots stored at −20 °C for future analysis.2.9. Statistics
Statistics were calculated using GraphPad Prism (v5). Unless
otherwise indicated, differences of the medians of non-parametric
data were analysed using either Mann–Whitney (for two groups) or
the Kruskal–Wallace test with Dunn's multiple comparison test (for
more than two groups). For the presentation of data with zero values
on graphs with log scales in Figs. 1B and 2A and B, data were
transposed by the addition of 0.1 (ELISA data) or 0.0001 (PMN data);
statistics were calculated with non-transposed data.3. Results
3.1. Inﬂammatory markers are elevated in CF BALF compared to controls
Total and differential cell counts were enumerated in BALF
specimens from CF and control patients. Total cell counts were
elevated 4 fold in BALF from CF patients compared to controls (CF:
1.4×106 cells/ml; IQR: 0.54–3.0 v. Controls: 0.35×106 cells/ml; IQR:
0.12–0.49) (pb0.001) (Fig. 1A). Elevated cell counts in CF were
dominated by neutrophils which were elevated 89 fold compared to
controls (CF: 0.62×106 cells/ml; IQR: 0.16–2.2 v. Controls 0.007×106
cells/ml; IQR: 0.0008–0.01) (pb0.001) (Fig. 1B). MNCs were more
modestly elevated by 3.5 fold in CF (CF: 0.34×106 cells/ml; IQR: 0.1–
0.65 v. Controls 0.096×106 cells/ml; IQR: 0.02–0.25) (pb0.05)
(Fig. 1C). The expression of key chemokines was measured in 32 CF
BALF specimens and 9 controls. Elevated PMN counts in CF BALF were
mirrored in expression of the neutrophil chemoattractant IL-8 which
was elevated 17.5 fold compared to controls (CF: 1122 pg/ml; IQR:
323–2133 v. Controls 64 pg/ml; IQR: 46–691) (pb0.01) (Fig. 1D). The
mononuclear cell chemoattractant, MCP-1 was also elevated in CF
BALF, albeit more modestly at 3.8 fold (CF: 692 pg/ml; IQR: 278–1128
v. Controls 182 pg/ml; IQR: 110–345) (pb0.05) (Fig. 1E).3.2. Expression of IL-6 and its soluble receptors sIL-6R and sgp130 in
BALF from CF patients
Expression of IL-6, sIL-6R and sgp130 is upregulated in many
inﬂammatory diseases but has not been examined in CF to date. In this
study, modest quantities of IL-6 were detected in 22/32 CF samples
(median concentration 50 pg/ml; IQR: 0–74) but were nevertheless
elevated compared to controls (pb0.01) where IL-6 was detected in
only one sample (Fig. 2A). Levels of sIL-6R in BALF samples from CF
patients were not signiﬁcantly different from those observed in BALF
from control patients (median concentration for CF 456 pg/ml; IQR:
228–704, median concentration for controls 349 pg/ml; IQR: 162–
522) (Fig. 2B). sIL-6Rwas detected in all samples tested, except one CF
sample. Similar to sIL-6R, sgp130 levels in CF patients were not
signiﬁcantly different to control patients (median concentration for
CF 6210 pg/ml; IQR: 4196–8473, median concentration for controls
5056 pg/ml; IQR: 4153–6317) (Fig. 2C). sgp130 was detected in all
samples tested.
3.3. BALF from CF patients degrades IL-6, sIL-6R and sgp130
Unregulated protease activity is well described in the lungs of CF
patients and we hypothesised that proteolytic destruction of IL-6
trans-signalling molecules may explain the low levels observed in CF
BALF. Initially the concentration of NE in BALF was assessed as a
marker of unregulated proteolytic activity. Free NE activity was found
in 18/32 CF BALF samples analysed (median activity in positive
samples: 81 nM, IQR: 37–643 nM). In the 21 CF BALF samples where
accurate differential counts were available, NE activity was associated
with greater numbers of PMN in BALF (pb0.01) (Fig. 3A). NE activity
was not detected in any of the control BALF samples. To test the ability
of CF BALF to degrade IL-6, sIL-6R and sgp130, 300 ng/ml of each
molecule was added to a 20% BALF solution in TBS and samples were
incubated at 37 °C for 60 min. Samples were analysed byWestern blot
to assess antigen loss after 60 min. The capacity to degrade IL-6, sIL-6R
and sgp130was associatedwith NE activity in BALF samples (Fig. 3B, C
and D). Densitometry was performed on blots to calculate antigen loss
for IL-6 and sIL-6R over this period. For both antigens, BALF samples
with detectable NE contained signiﬁcantly greater degradative
Fig. 3. Neutrophil elastase present in CF BALF is associated with degradation of IL-6, sIL-6R and sgp130. A) In the 21 CF BALF samples where accurate differential cell counts were
available, NE activity was more prevalent in samples with high PMN counts (pb0.01). B), C) and D) CF BALF samples with high NE activity (1, 2 and 3) or no detectable activity (4, 5
and 6) were tested for their ability to degrade IL-6, sIL-6R and sgp130. BALF was spiked with 300 ng/ml IL-6, sIL-6R or sgp130 and antigen recovery wasmeasured at 0 and 60 min by
Western blot using a speciﬁc polyclonal antibody. Control reactions in the absence of BALF are depicted in the ﬁrst lane (No BALF). E) and F) All available BALF samples were tested
for their ability to degrade IL-6 and sIL-6R by Western blot. % Antigen loss was calculated following densitometry of scanned blots. CF BALF with active elastase possessed
signiﬁcantly greater degradative activity compared to either NE negative samples (IL-6: pb0.001, sIL-6R: pb0.01) or non-CF control samples (IL-6: pb0.05, sIL-6R: pb0.001).
Data presented in panel C are from separate experiments which were each individually controlled but are presented in this way to allow comparison with panels B and D. (+ve,
positive; −ve, negative).
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pb0.001, sIL-6R; pb0.01) or control BALF samples (IL-6; pb0.05, sIL-
6R; pb0.001) (Fig. 3E and F).
3.4. Degradation of IL-6 and sIL-6R is due to serine proteases in CF BALF
Matrix metalloproteases (MMPs) and neutrophil derived serine
proteases (NSPs) are two major families of proteolytic enzymesparticipating in CF lung pathology. To investigate whether either of
these enzyme groups were responsible for the observed degradation
of IL-6 and sIL-6R we tested the ability of a number of protease
inhibitors to protect exogenously added proteins from degradation by
CF BALF. Serine protease inhibitors AAT (50 μg/ml) and PMSF (2 mM)
both protected IL-6 and sIL-6R from degradation by CF BALF (Fig. 4A
and B). By contrast the broad spectrum matrix metalloproteinase
(MMP) inhibitors GM6001 (25 μM) and 1,10-phenanthroline (5 mM)
Fig. 4. The ability of CF BALF to degrade IL-6 and sIL-6R is inhibited by serine protease inhibitors. CF BALF with conﬁrmed degradative activity towards IL-6 and sIL-6R was treated
with the MMP inhibitors 1,10-phenanthroline (5 mM) or GM6001 (25 μM) or the serine protease inhibitors PMSF (2 mM) or AAT (50 μg/ml) or left untreated. Samples were
subsequently spiked with 300 ng/ml IL-6 (panel A) or sIL-6R (panel B) and antigen recovery was measured by Western blot at 0 and 60 min. Data shown are representative of 3
independent experiments with BALF from 3 separate CF patients. The order of lanes in panel B has been rearranged to allow easier comparison with panel A.
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doses previously shown to effectively inhibit MMPs in vitro [25,26].
3.5. Supernatants from in vitro aged neutrophils contain free elastase
activity and degrade sIL-6R in vitro
The CF lung contains large numbers of neutrophils. Previous
studies have shown that these cells are amajor source of sIL-6R during
inﬂammatory responses. However, in diseases such as CF, large
numbers of necrotic neutrophils persist in the lung, releasing serine
proteases into the local airway. We addressed the capacity of protease
release under these circumstances to degrade sIL-6R. Neutrophils
isolated from the blood of normal healthy volunteers were cultured
for up to 24 h. Cell viability was assessed by ﬂow cytometry using
Annexin-V/ToPro3 at 0, 6, 12, and 24 h and supernatants were
collected to determine NE activity and capacity to degrade sIL-6R. As
expected, cultured neutrophils moved from a predominantly viable
phenotype (annexinV−/ToPro3−) to an apoptotic phenotype (annex-
inV+/ToPro3−) over the ﬁrst 12 h progressing to a late apoptotic/
necrotic phenotype (annexinV+/ToPro3+) by 24 h (Fig. 5A). Super-
natants from these cells were analysed for NE activity. NE activity in
these samples increased over the 24 hour period indicating the
release of NE by neutrophils as they progress through apoptosis to
necrosis (Fig. 5B). The ability of these supernatants to degrade sIL-6R
was tested. As predicted from the NE activity in these samples,
degradation of exogenously added sIL-6R was observed in a time
dependent manner (Fig. 5C). Interestingly, not all supernatants from
these experiments were capable of degrading sIL-6R which may
reﬂect the wide range of NE activity detected in these supernatants
and the relatively low level of NE activity released from these
neutrophils relative to that seen in CF BALF.
3.6. The three neutrophil derived serine proteases, NE, CG and PR3
degrade sIL-6R in a time and dose dependent manner leading to a loss of
activity
Neutrophils express three closely related serine proteases, NE, CG
and PR3, in a co-ordinated fashion. AAT and PMSF inhibit all three
proteases to different extents. The susceptibility of IL-6 to cleavage by
all three proteases has previously been shown [27] however we
wished to determine the relative ability of each of these proteases to
degrade sIL-6R. NE, CG and PR3, were used to treat 300 ng/ml sIL-6R.
A range of protease concentrations between 15 and 1000 nM were
used to reﬂect the original concentration of active NE measured in CF
BALF (IQR: 37–643 nM, reported in Section 3.3). When sIL-6R was
measured byWestern blot, a time and dose dependent degradation of
sIL-6R by all three proteases was evident (Fig. 6A). On the basis of
molar equivalence, CG was the most potent protease with maximal
degradation occurringwithin 60 min at a concentration of 250 nM. NEalso demonstrated potent activity at 250 nM but required up to 4 h for
almost complete degradation of sIL-6R to occur. PR3 was the least
active protease with minimal degradation of sIL-6R occurring in the
presence of 1000 nM protease after 1 h and complete degradation
being observed after 4 h in the presence of 500 nM of protease. As CG
was the most potent of the serine proteases in these experiments, its
effect on sIL-6R bio-activity was tested. sIL-6R treatedwith 500 nMCG
for 2 h at 37 °C was compared to native sIL-6R for its ability to induce
MCP-1 production in the A549 alveolar type-II epithelial cell line
when combined with IL-6. In this system, IL-6 has a modest impact on
MCP-1 production compared to untreated cells (MCP-1 production in
response to IL-6 was set at 100% and used to standardise between
experiments). sIL-6R when combined with IL-6 enhanced the MCP-1
production (225%, range 187–293%). Treatment of sIL-6R with CG
almost completely abolished IL-6 trans-signalling activity in this assay
(130%, range 119–143%) production compared to native sIL-6R
(p=0.038) (Fig. 6B).3.7. IL-6 protects sIL-6R from degradation by serine proteases
Ligand-receptor interactions commonly result in conformational
changes. We hypothesised that such conformational changes might
alter the susceptibility of the IL-6/sIL-6R complex to serine proteases.
To test this, 300 ng/ml of sIL-6R was incubated with 250 nM NE and
CG or 500 nM PR3 in the presence or absence of IL-6. sIL-6R was
modestly protected from degradation in the presence of 300 ng/ml IL-
6 and almost completely protected from NE and PR3 when 3000 ng/
ml was used (Fig. 7A). IL-6 offered relatively poor protection against
CG, although a lower molecular weight form of sIL-6R remained in the
presence of higher concentrations of IL-6 (Fig. 7A). The ability of IL-6
to protect sIL-6R from degradation by CF BALF, where multiple
proteases may be present at the same time, was also tested. In line
with our observations with puriﬁed proteases, we observed that a 10-
fold excess of IL-6 signiﬁcantly protected sIL-6R from degradation in
two of the three samples tested (Fig. 7B), indicating that in certain
situations this protective effect may operate in vivo.
To further investigate the importance of ligand/receptor interac-
tions on susceptibility to protease digestion, we took advantage of
HYPER-IL-6, a recombinant molecule consisting of a truncated sIL-6R
molecule covalently linked to IL-6 by a short peptide [28]. As IL-6 and
sIL-6R are unable to dissociate in this state, we postulated that HYPER-
IL-6 should also be resistant to serine protease mediated degradation.
When exposed to NSPs, HYPER-IL-6 was almost completely protected
from degradation by both CG (250 nM) and PR3 (500 nM) (Fig. 8A)
when compared to sIL-6R alone. Following treatment with NE, a
distinctive lower molecular weight band was visible by Western blot
(Fig. 8A). Further analysis of this band revealed that it was
immunoreactive with antibodies against both IL-6 and sIL-6R
Fig. 5. Ageing neutrophils release NE and are capable of degrading sIL-6R.
A) Neutrophils isolated from the blood of healthy adult donors were cultured at a
density of 2×106 cells/ml in serum free RPMI-1640. Cellular viability was measured by
ﬂow cytometry at 0, 6, 12 and 24 h using Annexin-V and ToPro-3. Neutrophils became
progressively apoptotic (Annexin-V+/ToPro-3−) over the 24 hour time course, with
late apoptotic/necrotic cells (Annexin-V+/ToPro-3+) emerging as soon as 6 h of
culture. B) NE activity was measured in the supernatants of these cells collected at each
of the timepoints. NE activity was evident as soon as 6 h of culture, reaching a peak at
24 h and mirroring the presence of necrotic cells in the culture. C) Supernatants
harvested from neutrophils at each of the timepoints were spiked with 150 ng/ml sIL-
6R. sIL-6R spiked supernatants were incubated at 37 °C for 60 min and sIL-6R
antigenicity was measured by Western blot. Supernatants harvested at 12 and 24 h
degraded sIL-6R in two of the four donors.
Fig. 6. Puriﬁed neutrophil derived serine proteases degrade sIL-6R in a dose and time
dependent manner. A) 300 ng/ml sIL-6R was incubated with a range of concentrations
(15 nm–1000 nM) of puriﬁed NE, CG or PR3. Samples were incubated at 37 °C for 0, 60,
120 and 240 min. Integrity of sIL-6R was measured by Western blot using a speciﬁc
polyclonal antibody. Western blots are representative of at least three independent
experiments. B) 300 ng/ml sIL-6R was treated with or without 500 nM CG for 120 min
at 37 °C. 50 μg/ml AAT was used to neutralise serine protease activity prior to the
addition of 300 ng/ml IL-6. Stimuli were diluted 1/10 into serum free DMEMwhichwas
used to stimulate A549 cells for 18 h. Control stimulations with IL-6, CG or sIL-6R in the
presence of AAT were also performed. IL-6 trans-signalling activity was determined by
measuring MCP-1 production by ELISA. Means and standard deviations for four
independent experiments are presented. Data are presented as % MCP-1 expression
compared to IL-6 alone (meanMCP-1 expression in response to IL-6=1146 pg/ml). CG
treatment of sIL-6R signiﬁcantly inhibited its ability to induce the expression of MCP-1
by A549 cells.
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HYPER-IL-6 molecule retaining components of both IL-6 and sIL-6R.
4. Discussion
Wehave assessed the expression of IL-6, sIL-6R and the inhibitor of
IL-6 trans-signalling, sgp130, in the lungs of patients with CF. Three
important observations arise from this study. First, in light of previous
reports describing unusually low IL-6 expression in lung secretions
from CF patients, we show that NSPs in CF BALF are capable of
proteolytically degrading IL-6. Secondly, we have for the ﬁrst time
described the expression of the IL-6 agonist, sIL-6R, and the potent
antagonist of IL-6 trans-signalling responses, sgp130 in this patient
group; the absence of an upregulated expression proﬁle for thesemolecules in CF BALF compared to controls was unexpected in light of
the evident inﬂammation, and contrasts with the situation in many
other inﬂammatory diseases. Finally, we have identiﬁed neutrophil
derived serine protease activity as the major mediator of degradation
of IL-6, sIL-6R and sgp130 in the CF lung.
Although this is the ﬁrst investigation of sIL-6R and sgp130
expression in CF patients, previous reports have described extremely
low or undetectable IL-6 in induced sputum from CF [21–23] and
others which could detect IL-6 found it to be expressed at levels not
signiﬁcantly different from disease free control patients [29]. Here, the
concentration of IL-6 detected in BALF from CF patients, although
signiﬁcantly different from control patients, wasmuch lower than IL-6
values reported in other inﬂammatory lung diseases such as diffuse
bronchiactesis [23], pneumonia [30], asthma [31] and neonatal
chronic lung disease [20]. The reported deﬁciency of IL-6 in CF
Fig. 7. IL-6 protects sIL-6R from proteolytic degradation by NSPs and CF BALF. A) 300 ng/ml sIL-6R was incubated with 250 nM CG or NE or 500 nM PR3 for 60 min at 37 °C in the
presence or absence of 300 ng/ml or 3 μg/ml IL-6 or BSA. sIL-6R antigen recovery was measured byWestern blot using a speciﬁc polyclonal antibody. 3 μg/ml IL-6 offered signiﬁcant
protection against all three NSPs, but most signiﬁcantly against NE and PR3. No protection was observed when BSA was used at 300 ng/ml or 3 μg/ml. Western blots are
representative of at least three independent experiments. B) 300 ng/ml sIL-6R in the presence or absence of 3 μg/ml IL-6 was incubated for 60 min at 37 °C with 20% CF BAL ﬂuid
previously shown to contain high NE activity. sIL-6R recovery in all samples was measured byWestern blot using a speciﬁc polyclonal antibody. Western blots are representative of
at least three independent experiments.
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epithelial cells from these patients spontaneously express more IL-6
than healthy control cells [32] and circulating IL-6 can be detected in
CF serum at levels which correlate with the acute phase C-reactive
protein [33]. Furthermore, as shedding of sIL-6R from the surface of
neutrophils and other cells has been identiﬁed as a major source of
this molecule during inﬂammation [1,11,34,35], the low level of sIL-
6R in neutrophil dominated CF BALF was unexpected. Likewise,
elevated expression of both sIL-6R and sgp130 has been reported in a
number of diseases [36] reﬂecting their importance in modulating the
activity of IL-6.
Unregulated proteolytic activity is a known contributor to
pathology in the CF lung and is implicated in the reduced expression
and activity of a number of important components of the immune
response [37]. Targeting of IL-6 by NSPs [27] has previously been
suggested as an explanation for the surprisingly low pulmonary
expression of IL-6 in CF patients [23] however, this is the ﬁrst study to
show speciﬁc proteolysis of this cytokine by serine proteases in CF
BALF. We also show that the ability of IL-6 to mediate normal
inﬂammatory responses is further compromised by the destruction of
sIL-6R and sgp130 in the CF lung. Degradation of both IL-6 and sIL-6R
is prevented by the serine protease inhibitors AAT and PMSF, but not
by the pan-MMP inhibitors, GM6001 and 1,10-phenanthroline. Using
puriﬁed protease preparations, we have shown that sIL-6R is alsoFig. 8. The recombinant IL-6/sIL-6R fusion molecule HYPER-IL-6 is resistant to NSP mediated
to 250 nM CG or NE or 500 nM PR3 for 120 min at 37 °C. Antigen integrity was measured by
three independent experiments is presented. B) HYPER-IL-6 was treated with or without N
tested in samples taken at 0 and 120 min using speciﬁc antibodies against sIL-6R (left panesusceptible to degradation by all three proteases with a hierarchy of
activity; CGNNENPR3. At 102–103 nM, the concentrations of puriﬁed
NSPs needed to achieve degradation of sIL-6R were broadly similar to
the concentrations of active NE detected in the CF BALF specimens
(101–103 nM). This study has not investigated the possibility that
proteases found in CF BALF may act upon IL-6 trans-signalling
molecules in an additive or synergistic fashion as has previously
been shown for NE and CG [38]. However, all three enzymes are found
in the same neutrophil azurophillic granules and their expression is
similarly regulated. Consequently, the occurrence of free CG and PR3
activity in lung secretions from CF patients mirrors that of NE [39,40]
and so they are likely to be able to act co-operatively upon target
substrates. Taken together, these data suggest that all three NSPs
participate in IL-6 and sIL-6R degradation in vivo. Data fromA549 cells
presented here shows that this degradation is sufﬁcient to function-
ally inactivate the trans-signalling capacity of sIL-6R and does not
merely represent a discrete cleavage event leading to loss of
antigenicity with the antibody used for Western blots.
The release of large amounts of NSPs into the extracellular
environment is by no means an inevitable feature of neutrophil
biology. The majority of NSPs found in the CF lung are released from
necrotic neutrophils which persist in the CF lung due to a failure of
normal apoptotic cell clearance [41]. In our study, even the relatively
modest NE activity released into supernatants from 2×106 neutrophilsdegradation. A) 300 ng/ml sIL-6R (left panel) or HYPER-IL-6 (right panel) was exposed
Western blot using antibodies against sIL-6R in samples taken at 0 and 120 min. One of
SPs as described in experiment A. Reactivity with antibodies against sIL-6R or IL-6 was
l) or IL-6 (right panel). One of three independent experiments is presented.
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described shedding of intact sIL-6R as part of the normal programme
of neutrophil apoptosis [11]. However in our study, degradation was
associated with the emergence of necrotic neutrophils and release of
NE. Notably, Chalaris et al. usedmuch shorter culture times than those
used here which may have led to the emergence of a predominantly
apoptotic phenotype in that study. Such cells are likely to have limited
NSP exposure compared to the conditions used here, particularly the
longer culture times and serum free conditions used to more closely
reﬂect the protease/anti-protease imbalance prevalent in the CF lung
[42]. It is also important to point out that CF neutrophils, in contrast to
neutrophils from healthy donors used here, exhibit accentuated NE
secretion and an exaggerated activation proﬁle [43,44] which may
result in more profound degradation by these cells.
Proteases such as the MMPs have well acknowledged roles in
inﬂuencing normal and pathological inﬂammatory responses through
the activation and inactivation of inﬂammatory mediators [45]. Even
during well regulated inﬂammatory responses in otherwise healthy
individuals, limited exposure to free or cell associated NSP activity is
likely to occur. It is possible that the NSP mediated destruction of IL-6
trans-signalling molecules described here is merely a pathological
manifestation of an otherwise important role played by these
enzymes in shaping and regulating normal inﬂammatory responses.
In this scenario, complexes formed between IL-6 and sIL-6R may
signiﬁcantly prolong the activity of IL-6 during inﬂammatory
responses. The ability of excess IL-6 to protect sIL-6R from
degradation by NE and PR3 is particularly interesting. This contrasts
with a previous study which described the inactivation of IL-6 by
inﬂamed cerebrospinal ﬂuid [27] where a complex between IL-6 and
sIL-6R was shown to protect IL-6 from inactivation by CG but not NE
or PR3. Here we observed that conversely, IL-6 offers relatively poor
protection to sIL-6R against CG. Furthermore, the sIL-6R which
remains following exposure to CG in the presence of IL-6 was of a
slightly lower molecular weight (as in Fig. 7A), suggesting that even
when IL-6 confers protection, limited truncation of sIL-6R still occurs.
The potency of CG towards IL-6/sIL-6R complexes may be explained
by previous data which show that CG can attack IL-6 at the Phe78-
Asn79 bond [27]. As this site is crucial for interactions with sIL-6R
[46,47], damage here may preclude substantial interactions with sIL-
6R leading to relatively ineffective protection against this NSP.
Although not addressed here, it is possible that sgp130 may also
play a protective role in complex with IL-6/sIL-6R and may itself be
protected from the proteolysis we have described in this study. In CF,
it is likely that the overwhelming NSP activity would leave little scope
for secreted IL-6 or liberated sIL-6R to form protective complexes,
perhaps explaining why we see so little of these molecules in CF BALF.
Interestingly however, the recombinant IL-6/sIL-6R fusion molecule,
HYPER-IL-6, displayed enhanced resistance to all proteases tested
including CG. As the Phe78-Asn79 bond of IL-6 is likely to be in close
proximity to sIL-6R in this molecule, CG may be unable to attack the
complex. We also noted that HYPER-IL-6 was susceptible to NE
proteolysis, leading to the formation of a truncatedmolecule retaining
components of both IL-6 and sIL-6R. Thismay reﬂect altered activity of
NE towards the shortened sIL-6R sequence used to express HYPER-IL-
6 [28]. Given the discrete cleavage pattern of HYPER-IL-6 in response
to NE, it is likely that completely protease resistant versions of this
molecule could be engineered. The development of protease resistant
molecules which can regulate leukocyte inﬁltration in vivo may offer
an attractive avenue for therapeutic intervention.
In conclusion, this study has described a functional deﬁciency of
the IL-6 trans-signalling pathway in the lungs of patients with CF. This
is the ﬁrst analysis of the complete IL-6 trans-signalling pathway in CF
patients and is the ﬁrst description of a deﬁciency of this pathway in
any population. These ﬁndings have a number of important implica-
tions. Firstly, experimental blockade of IL-6 trans-signalling in murine
models of peritoneal inﬂammation results in exaggerated andprotracted neutrophil inﬁltration as well as reduced neutrophil
apoptosis [1,12]. It is intriguing to suggest that trans-signalling may
similarly regulate inﬂammation in the lung, particularly since intra-
tracheal administration of IL-6 has been shown to attenuate LPS
induced neutrophil inﬁltration [2]. In this scenario, it is possible that a
deﬁciency of IL-6 trans-signalling may partially explain the protracted
and persistent neutrophil recruitment in lungs of CF patients.
Secondly, the identiﬁcation of serine protease activity as the
underlying cause of this deﬁciency and the identiﬁcation of enhanced
resistance to proteolysis in the recombinant IL-6/sIL-6R fusion protein
further support the use of protease inhibitors such as AAT in the
treatment of CF and open the possibility of future therapeutic
strategies using recombinant protease resistant molecules such as
HYPER-IL-6 to break the cycle of inﬂammatory cell recruitment in
these patients.
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